Business · Companies · 5 hrs ago
Grifols reports 28% higher nine-month profit and announces dividend
Spanish drugmaker Grifols reported €390 million in profit for the first nine months of 2026, up 28% from a year earlier.
Its Biopharma business, which makes plasma-derived medicines, drove growth, with revenue rising 7.1% in the period.
The company said better margins and cash generation, alongside lower debt, also supported its results.
Grifols announced a dividend of €0.15 per share, due to be paid on December 4.
It kept its financial targets for 2026, including a forecast of €500 million to €575 million in cash flow before mergers and acquisitions.
The company is still assessing a possible US listing for its Biopharma business, but has not said whether it will proceed.
Grifols reported net profit of €390 million for the first nine months of 2026, up 28.4% from a year earlier.
The company announced an interim dividend of €0.15 per share from its 2026 results, payable on December 4.
Revenue for the first nine months reached €5.614 billion, up 4.6% at constant exchange rates.
Adjusted EBITDA rose 5% to €1.392 billion, while net leverage fell to 3.98 times EBITDA.
Grifols maintained its financial targets for 2026 and said it was still evaluating a possible US Biopharma business listing.
The articles differ on third-quarter revenue: Cinco Días reports €2.04 billion, while Expansión reports €2.4 billion.
- Who
- Grifols, a Spanish pharmaceutical company.
- What
- It reported higher nine-month profit and announced a €0.15-per-share interim dividend.
- When
- The results were reported on November 2, 2026; the dividend is due on December 4.
- Where
- The company operates internationally; the possible listing under evaluation concerns its Biopharma business in the United States.
- Why
- Grifols attributed performance to growth in Biopharma, improved margins and profitability, and cash generation.
This story does not have two clearly opposing sides.
Grifols announced the closure of 29 centres in the United States to reduce costs.
The company’s net leverage ratio stood at 3.98 times EBITDA, down from 4.2 times a year earlier.
Grifols reported nine-month results and announced an interim dividend.
Grifols is scheduled to pay the €0.15-per-share dividend.
- Nine-month net profit
- €390 million, up 28.4%
- Nine-month revenue
- €5.614 billion, up 4.6% at constant exchange rates
- Adjusted EBITDA
- €1.392 billion, up 5.0%
- Net leverage
- 3.98 times EBITDA at September 2026
- Interim dividend
- €0.15 per share, payable December 4
- Possible listing
- US Biopharma business; still under evaluation
3 sources
What people are saying
The third-quarter results reflect the sustained execution of our plan, with growth in our main businesses translating into greater profitability and cash generation.
There is continued progress in executing our value-creation priorities.